Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer.

ABSTRACT: Triple negative breast cancer (TNBC) is the most aggressive breast cancer accounting for around 15% of identified breast cancer cases. TNBC lacks human epidermal growth factor receptor 2 (HER2) amplification, is hormone independent estrogen (ER) and progesterone receptors (PR) negative, and is not reactive to current targeted therapies. Existing treatment relies on chemotherapeutic treatment, but in spite of an initial response to chemotherapy, the inception of resistance and relapse is unfortunately common. Dasatinib is an approved second-generation inhibitor of multiple tyrosine kinases, and literature data strongly support its use in the management of TNBC. However, dasatinib binds to plasma proteins and undergoes extensive metabolism through oxidation and conjugation. To protect dasati

SUBMITTER: Bahman F 

PROVIDER: S-EPMC8234460 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature